Verge Genomics and AstraZeneca Join Forces in $42M Drug Discovery Partnership

Verge Genomics has entered into a four-year, $882 million deal with AstraZeneca's rare disease division, Alexion, focusing on undisclosed rare neurodegenerative and neuromuscular diseases. As part of the deal, AstraZeneca will pay Verge $42 million upfront, including equity and near-term payments, and will also take an equity stake in Verge.